Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

ÃÀ¸ß÷ÖúÁ¦ÓîÒ«ÉúÎïSTAT3Ë«Á×ËữÒÖÖÆ¼ÁYY201»ñÅúÁÙ´²

2023-07-27
|
»á¼ûÁ¿£º

2023Äê7ÔÂ20ÈÕ£¬£¬£¬£¬£¬ÉϺ£ÓîÒ«ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°ÓîÒ«ÉúÎ£©×ÔÖ÷Ñз¢µÄSTAT3Ë«¹¦Ð§Á×Ëữλµã°ÐÏòÒÖÖÆ¼Á¡ª¡ªYY201ÁÙ´²ÊÔÑéÉêÇëÕýʽ»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨NMPA£©Åú×¼£¬£¬£¬£¬£¬Ë³Ó¦Ö¢ÎªÍíÆÚʵÌåÁöºÍ¸´¾ÙÊÂÖÎÐÔ¶ñÐÔѪҺÖ×Áö¡£¡£¡£¡£¡£

ÃÀ¸ß÷£¨ÒÔϼò³Æ¡°ÃÀ¸ß÷¡±£©×÷ΪÓîÒ«ÉúÎïµÄÏàÖúͬ°é£¬£¬£¬£¬£¬ÎªYY201ÌṩÁËҩѧÑо¿Ð§ÀÍ£¨°üÀ¨ÖÊÁÏÒ©¡¢ÖƼÁ£©¡¢ÁÙ´²Ç°Ñо¿Ð§ÀÍ£¨°üÀ¨Ò©Ð§¡¢Ò©´ú¡¢°²ÆÀ£©ÒÔ¼°INDÉ걨ЧÀ͵ȣ¬£¬£¬£¬£¬ÖúÁ¦YY201ÀÖ³Éͨ¹ý IND ÉóÅú½øÈëÁÙ´²ÊÔÑé½×¶Î¡£¡£¡£¡£¡£

STAT3Ë«Á×ËữÒÖÖÆ¼ÁYY201

First-in-classС·Ö×Ó°ÐÏòÒ©Îï

STAT3ÓÉÓÚÆä°Ðµã½çÃæÏà¶Ôƽչ£¬£¬£¬£¬£¬ÎÞ·¨ÌṩС·Ö×ÓÌØÒìÐÔÁ¬ÏµµÄ¡°¿Ú´ü¡±½á¹¹£¬£¬£¬£¬£¬Êǹ«Èϵġ°ÄѳÉÒ©°Ðµã¡±¡£¡£¡£¡£¡£ÓîÒ«ÉúÎï¿ÆÑ§¼ÒÍŶÓһֱרעÓÚSTAT3°ÐµãµÄ»ù´¡ºÍת»¯Ñо¿£¬£¬£¬£¬£¬²¢½èÖúAI¼¼ÊõÊ״η¢Ã÷²¢¿ª·¢³öÁËÄÉĦ¶û¼¶STAT3Ë«Á×ËữλµãÒÖÖÆ¼Á¡¢È«ÇòÁìÏȵÄFirst-in-classС·Ö×Ó°ÐÏòÒ©Îï¡°YY201¡±¡£¡£¡£¡£¡£¸ÃÒ©Îïͨ¹ýÓëSTAT3Ö±½ÓÁ¬Ïµ£¬£¬£¬£¬£¬ÒÖÖÆSTAT3µÄ Tyr705ºÍSer727˫λµãÁ×Ëữ£¬£¬£¬£¬£¬ÒÖÖÆSTAT3¹¦Ð§ºÍ×è¶ÏÏÂÓÎÐźÅת´ï£¬£¬£¬£¬£¬´Ó¶øÊ©Õ¹ÒÖÖÆÖ×Áö×÷Óᣡ£¡£¡£¡£ÌåÍâÒ©ÀíѧºÍҩЧѧÑо¿Åú×¢£¬£¬£¬£¬£¬YY201ÓëSTAT3µÄÇ׺ͻîÐÔÔÚ1-10 ÄÉĦ¶û£¬£¬£¬£¬£¬ÔÚÒÈÏÙ°©¡¢ÈýÒõÐÔÈéÏÙ°©¡¢·Î°©¡¢¼±ÐÔËèϵ°×Ѫ²¡¡¢ÁܰÍÁöµÈʵÌåÖ×ÁöºÍѪҺÖ×ÁöµÄÌåÍâÔöÖ³ÒÖÖÆ»îÐÔÔÚ1-10 nM£¬£¬£¬£¬£¬ÔÚ¶àÖÖÌåÄÚÄ£×ÓÖÐÌåÏÖ³öÏÔÖøµÄ¿¹Ö×Áö×÷Ó㬣¬£¬£¬£¬¼«µÍ¼ÁÁ¿Ï¿ÉÖÂÖ×ÁöÍêÈ«ÏûÍË£¬£¬£¬£¬£¬Ò©´ú¶¯Á¦Ñ§ºÍ¶¾ÀíѧÑо¿Òà֤ʵYY201ÓÅÒìµÄ³ÉÒ©ÐÔºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£

ÍÆ¼öÔĶÁ£º    ÃÀÑÐ| STAT3¡ª¡ªÖ×ÁöÑо¿Óë°ÐÏòÖÎÁƵÄÈÈÃźòÑ¡Õߣ¡

YY201»ñµÃÁÙ´²»ñÅú²»µ«´ú±íÁËÓîÒ«ÉúÎïÓÖÒ»Ö÷ÒªÍ»ÆÆ£¬£¬£¬£¬£¬ÑéÖ¤ÁËÓîÒ«ÉúÎﳬµÈ·Ö×Ó½º¼¼Êõƽ̨ºÍAIÒ©Î︨Öú¿ª·¢Æ½Ì¨µÄÁ¢ÒìÄÜÁ¦£¬£¬£¬£¬£¬Í¬Ê±Ò²Ö¤ÊµÎúÃÀ¸ß÷ÁÙ´²Ç°Ñо¿µÄ¼¼ÊõЧÀÍʵÁ¦¡£¡£¡£¡£¡£

ÃÀ¸ß÷ÁÙ´²Ç°Ñо¿Ð§ÀÍÆ½Ì¨

һվʽÖúÁ¦Á¢ÒìÒ©ÎïÑз¢

ÔÚYY201µÄÁÙ´²Ç°Ñз¢ÖУ¬£¬£¬£¬£¬ÃÀ¸ß÷ҩѧÑо¿ºÍÁÙ´²Ç°Ñо¿°å¿éµÄÍŶӸ÷˾ÆäÖ°£¬£¬£¬£¬£¬²¢ÓëÓîÒ«ÉúÎïϸÃÜÅäºÏ£¬£¬£¬£¬£¬Öƶ©ÁËÑϽ÷çÇÃܵÄÊÔÑ鼯»®£¬£¬£¬£¬£¬Ð­µ÷¸÷Ñз¢ÊÔÑéÅÅÆÚ£¬£¬£¬£¬£¬´ÓÖÊÁÏÒ©¡¢ÖƼÁ¡¢Ò©Ð§¡¢Ò©´ú¡¢°²ÆÀÒÔ¼°INDÉ걨µÈ¶à·½ÃæÈ·±£ÁËÏîĿ˳ËìÍÆ½ø£¬£¬£¬£¬£¬ÎªÕâһȫÇòÊ×´´µÄÖØÁ¿¼¶ÐÂÒ©»ñÅúÁÙ´²ÌṩÁËÒªº¦Ö§³Ö¡£¡£¡£¡£¡£

³ýÁËҩѧÑо¿¡¢ÁÙ´²Ç°Ñо¿£¬£¬£¬£¬£¬ÃÀ¸ß÷ÁÙ´²ËÞÊÀÎïÒ½Ò©Ñз¢Ð§ÀÍÆ½Ì¨»¹¿ÉÌṩҩÎï·¢Ã÷ЧÀÍ¡£¡£¡£¡£¡£ÃÀ¸ß÷һվʽµÄÑз¢Ð§ÀÍÆ½Ì¨£¬£¬£¬£¬£¬Í¨¹ý¿ç²¿·Ö¸ßЧЭ×÷£¬£¬£¬£¬£¬¿ÉʵÏÖ1+1>2µÄЭͬЧӦ£¬£¬£¬£¬£¬¼ÓËÙÍÆ½øÐÂÒ©Ñз¢¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬ÃÀ¸ß÷´ÓÂѰ×Öʽµ½â¼¼ÊõµÄ¿¹Ìå¼°¿¹ÌåÒ©ÎïżÁª¼¼Êõ£¬£¬£¬£¬£¬´ÓÃâÒßÖÎÁƵ½°ÐÏòÖÎÁÆ£¬£¬£¬£¬£¬Ò»Á¬Á¢ÒìÍêÉÆÁ¢ÒìÒ©Ñз¢ÏµÍ³£¬£¬£¬£¬£¬Îª¸³ÄÜÁ¢ÒìÒ©ÎïµÄÑз¢´òÏÂÁ˼áʵ»ù´¡¡£¡£¡£¡£¡£

ÃÀ¸ß÷ףºØÓîÒ«ÉúÎïYY201»ñÅúÁÙ´²£¬£¬£¬£¬£¬ÆÚ´ý¸ÃÒ©ÁÙ´²ÊÔÑé˳Ë쿪չ£¬£¬£¬£¬£¬¿ÉÒÔÔçÈÕÉÏÊУ¬£¬£¬£¬£¬Ô츣²¡»¼£¬£¬£¬£¬£¬Í¬Ê±ÆÚ´ýÓîÒ«ÉúÎïÔÚFICÖлñµÃ¸ü¶àÁ¢ÒìЧ¹û¡£¡£¡£¡£¡£ÃÀ¸ß÷ҲÆÚ´ý¿ÉÒÔÒ»Á¬ÖúÁ¦ÐÂÒ©Ñз¢£¬£¬£¬£¬£¬Óë¿Í»§ÏàÖú¹²Ó®£¬£¬£¬£¬£¬¼ùÐÐÐÐҵʹÃü£¡


¹ØÓÚÓîÒ«ÉúÎï

ÉϺ£ÓîÒ«ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾ÊÇÒ»¼ÒAI¸³ÄÜ¡¢Á¢ÒìÒýÁ죬£¬£¬£¬£¬¾Û½¹Ð¼¼ÊõºÍаеãµÄÐÂÒ©Ñз¢ÆóÒµ¡£¡£¡£¡£¡£¹«Ë¾ÓÐÈý´ó¹ú¼ÊÒ»Á÷ÐÂÒ©Ñз¢Æ½Ì¨ºÍ¶à¸ö×ÔÖ÷Ô­´´²úÆ·¹ÜÏߣ¬£¬£¬£¬£¬½¹µã²úÆ·ÏÖÔÚÕýÔÚ¾ÙÐÐ×¢²áÁÙ´²Ñо¿¡£¡£¡£¡£¡£²úÆ·¹ÜÏßYY001ÊÇͨ¹ý°ÐÏòÖ×ÁöÃâÒß΢ÇéÐΣ¬£¬£¬£¬£¬ÖÎÁÆPD-1¿¹ÌåÃô¸ÐºÍ²»Ãô¸ÐµÄÍíÆÚʵÌåÁö£¬£¬£¬£¬£¬¼´½«¿ªÕ¹ÁÙ´²2ÆÚÑо¿£¬£¬£¬£¬£¬ÊÇÒ»¸öÓÐDZÁ¦³ÉΪȫÇò×îÓŵÄÃâÒß΢ÇéÐÎÞ׿¹¼Á¡£¡£¡£¡£¡£²úÆ·YY201ÊÇÈ«ÇòÊ×´´µÄת¼Òò×ÓÒÖÖÆ¼Á£¬£¬£¬£¬£¬¼´½«¿ªÕ¹ÖÐÃÀÁÙ´²1ÆÚÑо¿£¬£¬£¬£¬£¬Î´À´ÆäËû²úÆ·¹ÜÏßÒ²¼´½«Â½Ðø½øÈëÁÙ´²¡£¡£¡£¡£¡£¹«Ë¾ÏÖÔÚÒÑÉêÇë·¢Ã÷רÀû20ÓàÏͨ¹ýPCT¹ú¼ÊÉêÇëÀֳɽøÈëÅ·¡¢ÃÀ¡¢ÈÕ¡¢¼Ó¡¢°ÄµÈ¹ú¼ÒÓëµØÇø¡£¡£¡£¡£¡£

¹«Ë¾ÏÖÔÚÒÑÓв©Ê¿ºÍ˶ʿԱ¹¤50ÓàÃû£¬£¬£¬£¬£¬ÔÚÉϺ£ãÉÐÐÇøÓµÓÐ5000ÓàÆ½µÄÑз¢ºÍ°ì¹«Ô°µØ£¬£¬£¬£¬£¬ÀÛ¼ÆÒÑÍê³ÉÊýÒÚԪרҵ»ú¹¹Í¶×Ê¡£¡£¡£¡£¡£ÏȺó»ñµÃ¹ú¼Ò¿Æ¼¼²¿Ç㸲ÐÔ¼¼ÊõÁ¢Òì´óÈüÌìÏÂÓÅÒì½±¡¢ÍÅÖÐÑë ¡°´´Çà´º¡±ÖйúÇàÄêÁ¢Òì´´Òµ´óÈüÌìϽ𽱡¢¹ú¼ÒÈËÉ粿µÚÒ»½ì²©Ê¿ºóÁ¢Òì´´Òµ´óÈüÌìϽ𽱺͹ú¼Ò½ÌÓý²¿¡°»¥ÁªÍø+¡±´óѧÉúÁ¢Òì´´Òµ´óÈüÌìÏÂÒø½±µÈÉùÓþ¡£¡£¡£¡£¡£


¹ØÓÚÃÀ¸ß÷

ÃÀ¸ß÷£¨¹ÉƱ´úÂ룺688202.SH£©½¨ÉèÓÚ2004Ä꣬£¬£¬£¬£¬×ܲ¿Î»ÓÚÉϺ££¬£¬£¬£¬£¬ÖÂÁ¦ÓÚΪȫÇòÖÆÒ©ÆóÒµ¡¢Ñо¿»ú¹¹¼°¿ÆÑÐÊÂÇéÕßÌṩȫ·½Î»µÄÁÙ´²Ç°ÐÂÒ©Ñо¿Ð§ÀÍ¡£¡£¡£¡£¡£ÃÀ¸ß÷µÄһվʽ×ÛºÏЧÀÍÒÔÇ¿ÓÐÁ¦µÄÏîÄ¿¹ÜÀíºÍ¸ü¸ßЧ¡¢¸ßÐԼ۱ȵÄÑз¢Ð§ÀÍÖúÁ¦¿Í»§¼ÓËÙÐÂÒ©Ñз¢Àú³Ì£¬£¬£¬£¬£¬Ð§Àͺ­¸ÇÒ½Ò©ÁÙ´²Ç°ÐÂÒ©Ñо¿µÄÈ«Àú³Ì£¬£¬£¬£¬£¬°üÀ¨Ò©Îï·¢Ã÷¡¢Ò©Ñ§Ñо¿¼°ÁÙ´²Ç°Ñо¿¡£¡£¡£¡£¡£ÖÁ2022Ä©£¬£¬£¬£¬£¬ÃÀ¸ß÷ÒÑΪȫÇò³¬1840¼Ò¿Í»§ÌṩҩÎïÑз¢Ð§ÀÍ£¬£¬£¬£¬£¬¼ÓÈëÑз¢Íê³ÉµÄÐÂÒ©¼°·ÂÖÆÒ©ÏîÄ¿ÒÑÓÐ330¼þIND»ñÅúÁÙ´²£¬£¬£¬£¬£¬Ó뺣ÄÚÍâÓÅÖʿͻ§ÅäºÏÉú³¤¡£¡£¡£¡£¡£ÃÀ¸ß÷½«¼ÌÐø×¤×ãÈ«ÇòÊÓÒ°£¬£¬£¬£¬£¬¾ÛÁ¦ÖйúÁ¢Ò죬£¬£¬£¬£¬ÎªÈËÀ࿵½¡Ð¢Ë³ÊµÁ¦£¡

Ïà¹ØÐÂÎÅ
Ñо¿Ö°Ô±Éè¼ÆºÏ³ÉSTAT3ºÍHDAC˫ͨ·ÒÖÖÆ¼ÁÓÃÓÚÖÎÁÆÊµÌåÖ×Áö£¬£¬£¬£¬£¬PKʵÑéͨ¹ýÃÀ¸ß÷¾ÙÐÐ
2023-07-05
The inhibition of HDACs will lead to compensated activation of a notorious cancer-related drug target, STAT3, in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors. Herein, researchers synthesized a series of potent pterostilbene hydroxamic acid derivatives with dual-target inhibition activity. The pharmacokinetic experiment in SD Rats was carried out by Medicilon.
ÃÀÑÐ| STAT3¡ª¡ªÖ×ÁöÑо¿Óë°ÐÏòÖÎÁƵÄÈÈÃźòÑ¡Õߣ¡
2023-08-09
°ÐÏò STAT3 ÐźÅͨ·ÒѳÉΪÐí¶à°©Ö¢µÄDZÔÚÖÎÁƲßÂÔ¡£¡£¡£¡£¡£ÃÀ¸ß÷¿ÉÒÔΪ¿Í»§ÌṩSTAT3Ò©Îï·¢Ã÷¡¢Ò©Ñ§Ñо¿£¨ÖÊÁÏÒ©¹¤ÒÕ¿ª·¢+ÖÆ¼Á£©¡¢ÁÙ´²Ç°Ñо¿Ð§ÀÍ£¨°üÀ¨Ò©Ð§¡¢Ò©´ú¡¢°²ÆÀ£©ÒÔ¼°INDÉ걨µÈһվʽЧÀÍ¡£¡£¡£¡£¡£
ÃÀ¸ß÷ÖúÁ¦ | ÓîÒ«ÉúÎïSTAT3Ë«Á×ËữλµãÒÖÖÆ¼ÁYY201ÀÖ³ÉÍê³ÉÖÐÃÀË«±¨
2023-11-23
ÃÀ¸ß÷×÷ΪÓîÒ«ÉúÎïµÄÏàÖúͬ°é£¬£¬£¬£¬£¬ÎªYY201ÌṩÁËҩѧÑо¿Ð§ÀÍ£¨°üÀ¨ÖÊÁÏÒ©¡¢ÖƼÁ£©¡¢ÁÙ´²Ç°Ñо¿Ð§ÀÍ£¨°üÀ¨Ò©Ð§¡¢Ò©´ú¡¢°²ÆÀ£©ÒÔ¼°INDÉ걨ЧÀ͵ȣ¬£¬£¬£¬£¬ÖúÁ¦YY201ÀÖ³ÉÍê³ÉÖÐÃÀË«±¨¡£¡£¡£¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿